Tanaka Shingo, Nakada Mitsutoshi, Nobusawa Sumihito, Suzuki Satoshi O, Sabit Hemragul, Miyashita Katsuyoshi, Hayashi Yutaka
Division of Neuroscience, Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.
Brain Tumor Pathol. 2014 Jul;31(3):172-6. doi: 10.1007/s10014-014-0192-2. Epub 2014 Jun 4.
Pleomorphic xanthoastrocytoma (PXA) is classified by the World Health Organization as a grade II astrocytic tumor with relatively favorable prognosis among gliomas. A valine-to-glutamic acid substitution at position 600 of the serine/threonine-protein kinase BRAF (BRAF V600E) mutation, which is commonly found in PXA, has recently been detected in approximately 50% of all epithelioid glioblastoma (GBM) cases. We herein report a case of epithelioid GBM developing at the site of a left temporal PXA 13 years after the treatment of the primary tumor. The BRAF V600E mutation was detected in both tumors. These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation.
多形性黄色星形细胞瘤（PXA）被世界卫生组织归类为II级星形细胞瘤，在胶质瘤中预后相对较好。丝氨酸/苏氨酸蛋白激酶BRAF（BRAF V600E）突变的第600位缬氨酸到谷氨酸的替代，常见于PXA，最近在所有上皮样胶质母细胞瘤（GBM）病例中约50%检测到。我们在此报告一例原发性肿瘤治疗13年后，在左颞叶PXA部位发生的上皮样GBM病例。在两个肿瘤中均检测到BRAF V600E突变。这些发现表明上皮样GBM可能起源于具有BRAF V600E突变的PXA。
